The rise of non-standard healthcare benefits: Healix

Neurodevelopmental, fertility and gender dysphoria benefits

Jaskeet Briah
clock • 5 min read

As demand for non-standard healthcare benefits rises for Healix, Jaskeet Briah, reporter, COVER, speaks with the firm’s head of clinical operations, Keira Wallis, about how corporate healthcare offerings are evolving to focus more on women’s health and mental health.

Corporate healthcare trust, Healix, has found the number of companies offering neurodevelopmental benefits to their employees has jumped by 500% since 2022. Firms offering gender dysphoria benefits has also risen by 500% since 2021 and new companies introducing fertility benefits increased by 86% from 2020 to 2023.  While a range of industries are looking to introduce these benefits to employees, both the financial services and the professional services sectors are leading the way.  Regarding neurodevelopment benefits, Healix has seen almost an even split in usage by males (51...

To continue reading this article...

Join COVER for free

  • Unlimited access to real-time news, key trend analysis and industry insights.
  • Stay on top of the latest developments around health and wellbeing, diversity and inclusion and the cost of living crisis.
  • Receive breaking news stories straight to your inbox in the daily newsletter.
  • Members only access to monthly programme 'The COVER Review'
  • Be the first to hear about our CPD accredited events and awards programmes.

Join now

 

Already a Cover member?

Login

More on Employee Benefits

Cancer carers to cost UK employers £8.5bn in 2025

Cancer carers to cost UK employers £8.5bn in 2025

Impact on finances, time, careers

Cameron Roberts
clock 28 March 2025 • 3 min read
Howden snaps up Barnett Waddingham

Howden snaps up Barnett Waddingham

Provides platform for expansion in global markets

Jaskeet Briah
clock 25 March 2025 • 2 min read
PIB Employee Benefits acquires Amba

PIB Employee Benefits acquires Amba

Technology acquisition

Cameron Roberts
clock 24 March 2025 • 1 min read